Science ministries push thematic clustering of Startups at review meeting (See 'Corp Brief') Nearly 100 delegates from over 70 countries to participate at ECI event (See 'Corp Brief') A&C - Bill discounting is short-term, high-risk commercial financing mechanism where elevated interest rates are neither unusual nor inherently unfair: SC (See 'Legal Desk') CEA has successfully conducted 220 elections; 70 elections currently underway (See 'Corp Brief') Service Matter - Government is bound by same limitation laws as any other party; delay caused by bureaucratic procedures cannot be mechanically condoned: HC (See 'Legal Desk') Khattar inaugurates Centre of Excellence for power sector regulatory affairs at Delhi IIT (See 'Corp Brief') Misc - Civil suit seeking cancellation of a registered sale deed is barred u/s 34 of SARFAESI Act when SARFAESI measures have been initiated: HC (See 'Legal Desk') Port, Inland Waterways Projects Worth Rs 552 Crore launched to boost Riverine Logistics (See 'Corp Brief') Manjhi inaugurates PM Vishwakarma Haat 2026 in New Delhi (See 'Corp Brief') PMLA - If property is attached for value thereof to proceeds of crime, it happens when proceeds of crime acquired or obtained directly or indirectly is not available in hands of person: SAFEMA (See 'Legal Desk') AIIA celebrates National Startup Day 2026 (See 'Corp Brief') SEBI - Proposed Acquirer shall be exempted from complying with requirements of sub-regulation (1) of regulation 3 and regulation 4 of SAST Regulations, 2011 with respect to direct acquisition in Target Company: SEBI (See 'Legal Desk') CCPA takes action against unauthorized sale of Walkie-Talkies on E-Com Platforms (See 'Corp Brief') IBC - Status of financial creditor is granted to individual allottees u/s 5(8)(f) of IBC, but this status does not extend to society they are members of, as society is distinct juristic entity: SC (See 'Legal Desk') IICA launches registration for Post Graduate Insolvency Programme (See 'Corp Brief') IBC - 'Pre-existing dispute' capable of barring initiation of CIRP u/s 9 IBC must be genuine and supported by substantive evidence, and not moonshine defence raised merely to obstruct CIRP: SC (See 'Legal Desk') Rs 1 Lakh Crore R&D Fund to propel Deep Tech Research: Goyal (See 'Corp Brief') A&C - Mere commercial relationship or marking of emails to principal employer does not establish legal intent to bind third-party sub-vendor to main arbitration agreement: SC (See 'Legal Desk') Govt positions Tribal Healers as Partners in Tribal Health Transformation (See 'Corp Brief') A&C - High Courts cannot effectively act as appellate court, re-appreciate evidence, and substitute its own interpretation in place of arbitral award: SC (See 'Legal Desk') India's Textile & Apparel Exports maintain growth momentum amid global headwinds (See 'Corp Brief') A&C - Arbitral tribunals must first look to contract that defines legal relationship between parties: SC (See 'Legal Desk') Ministry of Coal executes Agreements for 3 Blocks with Damodar Valley Corporation (See 'Corp Brief') IBC - Directors/ promoters cannot be exposed to personal liability through execution, in absence of prior and reasoned determination justifying disregard of corporate personality: SC (See 'Legal Desk') 'Jo Vaada Kiya, Wo Nibhana Padega' - Promissory Estoppel Reaffirmed: Supreme Court Reiterates the Rules of State Accountability (See CORP EINSICHT)

Print

Glenmark's Swiss arm gets nod to market Ryaltris nasal spray in Russia

Published: Feb 22, 2021

By TIOLCORPLAWS News Service

NEW DELHI, FEB 22, 2021: GLENMARK Pharmaceuticals on Monday said its Swiss subsidiary, Glenmark Specialty, has received marketing approval from Russian health regulators for its fixed-dose combination nasal spray, Ryaltris.

Ryaltris is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis, like stuffy and runny nose, nasal itching, sneezing, as well as irritated eyes, in adults and children over 12 years of age.

"Glenmark has built strong capabilities in the area of respiratory medicine and is among the leading players in this therapy area across several markets globally. Russia is one of the key markets for us and we are consistently looking to expand our product portfolio," said Csaba Kantor, Senior Vice President - Russia and CIS region, Glenmark.

In Russia, allergic rhinitis affects 10-20 per cent of the population on average, with certain regions having a higher prevalence rate of 18-38 per cent.

"Glenmark has a strong established presence in Russia for over 30 years, which will enable us to lead the commercialization of this product in the country. We look forward to being able to make this innovative product available to patients in Russia as soon as possible," Mr Kantor added.

The company estimated that Ryaltris will be available to patients in Russia by the first quarter of 2021-22.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.